Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2026)

Cogent Biosciences' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 97212000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 35.05% year-over-year to 97212000.0; the TTM figure through Mar 2026 stood at 346967000.0 (down 27.8% YoY), while the FY2025 annual figure was 321736000.0, down 24.78% from the prior year.
• Income from Continuing Operations was 97212000.0 for Q1 2026 at Cogent Biosciences, down from 95305000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 31311000.0 in Q1 2022 to a low of 97212000.0 in Q1 2026.
• Historically, Income from Continuing Operations has averaged 59747176.47 across 5 years, with a median of 58347000.0 in 2024.
• The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations plunged 147.03% in 2022, then dropped 14.57% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 41635000.0 in 2022, then sank by 30.56% to 54358000.0 in 2023, then slipped by 28.55% to 69875000.0 in 2024, then tumbled by 36.39% to 95305000.0 in 2025, then slipped by 2.0% to 97212000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 97212000.0 (Q1 2026), 95305000.0 (Q4 2025), and 80927000.0 (Q3 2025), per Business Quant data.